



April 20, 2018

Simon Castellanos, CEO  
Bond Pharmacy, Inc. dba Advanced Infusion Solutions  
623 Highland Colony Pkwy, Suite 100  
Ridgeland, Mississippi 39157-6077

Mr. Castellanos:

We are enclosing a copy of the Establishment Inspection Report (EIR) for the inspection conducted at your facility, Bond Pharmacy, Inc. dba Advanced Infusion Solutions, located at 623 Highland Colony Pkwy, Suite 100, Ridgeland, Mississippi 39157- 6077, from November 6, 2017, to November 15, 2017, by the U.S. Food and Drug Administration (FDA). In addition, we are enclosing the letter sent to the Mississippi State Board of Pharmacy for follow up.

When the Agency concludes that an inspection is “closed” under 21 C.F.R. 20.64(d)(3), it will release a copy of the EIR to the inspected establishment.

The Agency continually works to make its regulatory process and activities more transparent for regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 C.F.R. Part 20. This, however, does not preclude you from requesting and possibly obtaining any additional information under FOIA.

If there is any question about the released information, please contact Mark Rivero at (504) 846-6103 or by email at [Mark.Rivero@fda.hhs.gov](mailto:Mark.Rivero@fda.hhs.gov).

Sincerely,

John W. Diehl -S

Digitally signed by John W. Diehl -S  
DN: c=US, o=U.S. Government, ou=HHS,  
ou=FDA, ou=People, cn=John W. Diehl -S,  
0.9.2342.19200300.100.1.1=2000099727  
Date: 2018.04.20 23:30:22 -05'00'

LCDR John W. Diehl, M.S.  
Director, Compliance Branch  
Office of Pharmaceutical Quality Operations,  
Division II

Enclosure: EIR, SHL

U.S. Food & Drug Administration  
Office of Pharmaceutical Quality Operations, Division 2  
4040 N. Central Expressway, Suite 300  
Dallas, Texas 75204  
[www.fda.gov](http://www.fda.gov)